Table 2. Overview on median OS times by... | American Society of Hematology

Table 2.

Overview on median OS times by genetic marker

Genetic marker	Median OS, mo	Reference
Favorable-risk group
Mutated NPM1 (FLT3-ITD^neg, NRAS^wt, KRAS^wt, TP53^wt)	39	4
Mutated IDH2 (FLT3-ITD^neg, NRAS^wt, KRAS^wt, TP53^wt)	37	4
Mutated IDH1∗ (TP53^wt)	29	6,17
Mutated DDX41	>24	3,13
AML with MR gene mutations (FLT3-ITD^neg, NRAS^wt, KRAS^wt, TP53^wt)	23	4
Intermediate-risk group
AML with MR gene mutations (FLT3-ITD^pos and/or NRAS^mut and/or KRAS^mut; TP53^wt)	13	4
Other cytogenetic and molecular abnormalities (FLT3-ITD^pos and/or NRAS^mut and/or KRAS^mut; TP53^wt)	12	4
Adverse-risk group
Mutated TP53	5-8	3,4,7,10,14-16

Genetic marker	Median OS, mo	Reference
Favorable-risk group
Mutated NPM1 (FLT3-ITD^neg, NRAS^wt, KRAS^wt, TP53^wt)	39	4
Mutated IDH2 (FLT3-ITD^neg, NRAS^wt, KRAS^wt, TP53^wt)	37	4
Mutated IDH1∗ (TP53^wt)	29	6,17
Mutated DDX41	>24	3,13
AML with MR gene mutations (FLT3-ITD^neg, NRAS^wt, KRAS^wt, TP53^wt)	23	4
Intermediate-risk group
AML with MR gene mutations (FLT3-ITD^pos and/or NRAS^mut and/or KRAS^mut; TP53^wt)	13	4
Other cytogenetic and molecular abnormalities (FLT3-ITD^pos and/or NRAS^mut and/or KRAS^mut; TP53^wt)	12	4
Adverse-risk group
Mutated TP53	5-8	3,4,7,10,14-16

Favorable risk (median OS time) applies specifically to patients treated with AZA + IVO, irrespective of the presence of activating signaling gene mutations.